LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

B. Besse; E. Felip; B.C. Cho; T. Takahashi; Katerina Politi; J. Wang; G. De Castro; A. Kowalczyk-Tekiela; L. Bonanno; A.S. Muntean; G. Lo Russo; J. Fuentes Pradera; S.H. Kim; Marie Florescu; P. Chen; Elvire Pons-Tostivint; Y. Chepka; H. Mann; J. Rogerio; P.M. Forde

doi:10.1016/j.esmoop.2026.106957

LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

ESMO Open 2026 Open access

Read full text

Authors: B. Besse, E. Felip, B.C. Cho, T. Takahashi, Katerina Politi, J. Wang, G. De Castro, A. Kowalczyk-Tekiela, L. Bonanno, A.S. Muntean, G. Lo Russo, J. Fuentes Pradera

+8 more

S.H. Kim, Marie Florescu, P. Chen, Elvire Pons-Tostivint, Y. Chepka, H. Mann, J. Rogerio, P.M. Forde

DOI: 10.1016/j.esmoop.2026.106957

Cited by: 2

Abstract

Pts with advanced NSCLC and disease progression on or after anti-PD-(L)1 ± platinum-based CT (concurrent or sequential) have limited treatment (tx) options. The phase 3, randomized, open-label, multicentre LATIFY study (NCT05450692) evaluated C (a selective inhibitor of the ATR DNA damage response kinase) + D (anti-PD-L1) vs docetaxel in pts with LA/mNSCLC, without actionable genomic alterations, after progression on or after anti-PD-(L)1 and platinum-based CT. We report results of the primary and final analysis.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways

Publication details

Journal / source: ESMO Open
Publisher: Elsevier BV
Volume: 11
Pages: 106957–106957
Publication date: 17 March 2026
Language: EN